IC-OS Working Group Webinar - Cardiac Amyloidosis: A Zebra or a Horse? Treatment of Cardiac Amyloidosis

Ashutosh Wechalekar is Professor of Medicine and Haematology at University College London and Honorary Consultant Haematologist at University College London Hospital/Royal Free Hospital, London, UK. His clinical and research is focused on amyloidosis with a particular interest in cardiac amyloidosis. He leads the AL program for UK. His is the director of the Jack O’Neil Amyloidosis laboratory which is focused on amyloid typing and genomics. He leads UK’s first dedicated amyloidosis treatment clinic at University College London Hospitals and is leading development of a UK National Amyloidosis Treatment Network. He leads AL amyloidosis treatment and research in the UK. His research interests including the development of better risk stratification of the disease, reducing early cardiac mortality in AL, imaging, clonal biology and new treatment strategies in AL amyloidosis. He leads on several national and international clinical trials in AL amyloidosis and myeloma at UCL and has published extensively in the respective areas.

Dr Lenihan has been active in cardio-oncology and heart failure, for over 20 years. The main focus of these efforts have included hemodynamic assessments, angiogenic growth factor response, novel cardiac biomarkers as well as optimal methods to prevent or detect heart failure at the earliest stage possible in patients undergoing treatment for cancer. His current research projects include early phase clinical trials in cardio-oncology, heart failure and amyloidosis. He is the Principal Investigator of the PROTECT study looking at cardiac safety in patients undergoing proteasome inhibitor treatment for relapsed multiple myeloma and the recently completed PREDICT study, a large multicenter prospective study examining the role of cardiac biomarkers for the detection of cardiotoxicity during anthracycline based therapy. In addition, he is intimately involved in the latest treatment trials for cardiac amyloidosis. He was recently at Washington University in St Louis to enhance and expand the Cardio-Oncology Center of Excellence. He is at the forefront of concerted efforts to develop a viable Cardio-Oncology fellowship training program and continues to foster collaboration among a host of colleagues both regionally, nationally, and throughout the world. He is the current President of the International Cardio-Oncology Society (ICOS),www.IC-OS.org, which is an international professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.

Richard Cheng, MD, MSc is a HF cardiologist and cardio-oncologist with a focus on education, risk stratification, imaging, and treatment strategies for HF, cardiomyopathies, cardiac amyloidosis and cancer therapy-associated cardiac dysfunction. His recent research interests include the prevention of cardiovascular disease, epidemiology, and long-term cardiovascular complications of cancer treatment in breast cancer survivors and stem cell transplant recipients. He also has ongoing studies focused on risk stratification, multimodality imaging and outcomes in cardiac amyloidosis, cardiomyopathies, heart transplantation and LVAD recipients. He serves on the editorial boards of JACC, JACC: Cardio-Oncology, ACC.org, Heart, and the Journal of Heart and Lung Transplantation.